Sovaldi tablets 400 mg for hepatitis C (Sofosbuvir)

What are Sovaldi tablets 400 mg for Hepatitis C (Sofosbuvir)?

Sovaldi is a medication that contains the active principle sofosbuvir, which is primarily used for the treatment of chronic hepatitis C virus (HCV) infection. The mechanism of action of Sovaldi involves targeting a key enzyme called NS5B RNA-dependent RNA polymerase, which is essential for the replication of the hepatitis C virus. By inhibiting this enzyme, Sovaldi interferes with the viral replication process, ultimately leading to a reduction in the viral load within the patient's body.

Sofosbuvir, as an oral prodrug, gets converted into its active form within the body. This active form then competes with the natural building blocks required for viral RNA replication, thus suppressing the virus's ability to multiply. This antiviral effect results in a decline in HCV RNA levels, improved liver function, and potentially a sustained virologic response, which means the virus is undetectable in the blood for a certain period after treatment completion.

Effectiveness of Sovaldi with sofosbuvir has been well-documented in various clinical trials and real-world studies. The medication has shown high efficacy in achieving sustained virologic response rates across different HCV genotypes and patient populations. It has demonstrated particular success in cases where previous treatments had failed, and in individuals with coexisting liver conditions, such as cirrhosis.

However, it's important to note that the effectiveness of Sovaldi can vary depending on factors like the specific HCV genotype, the presence of liver cirrhosis, and the patient's overall health status. Nevertheless, the medication's benefits in terms of its antiviral efficacy have marked a significant advancement in the management of chronic hepatitis C, contributing to improved patient outcomes and reduced disease transmission. 

Active principles: sofosbuvir

Amount: 14 tablets

Maker: Gilead Sciences K. K., Tokyo, Japan

Indications: treatment of hepatitis C in patients with genotype 2 (serotype 2) or in  patients who do not belong to either genotype 1 or 2.

How to take

Patients with serotype 2 (genotype 2) should take 1 tablet a day for 12 weeks.

Patients not belonging to serogroup 1 or 2 (genotype 1 or 2) should take 1 tablet a day for 24 weeks.

This medicine should be taken together with ribavirin.

Contraindications: do not use for the following patients:

• patients with kidney dysfunction,
• patients with hepatitis B or its history,
• breastfeeding women,
• pregnant or possibly pregnant women.

Important information

Avoid taking any food or supplement containing  St. John's wort while taking this medicine. 

When used together with ribavirin, patient should avoid their own pregnancy or the pregnancy of their partner during all the course of treatment and at least 6 months after it.

Breastfeeding is strictly prohibited while using this medicine. 

If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.